A randomized, double-blind, placebo-controlled study to evaluate sildenafil, ambrisentan combination therapy in pulmonary hypertension, particularly of Eisenmenger syndrome

A randomized, double-blind, placebo-controlled study to evaluate sildenafil, ambrisentan combination therapy in pulmonary hypertension, particularly of Eisenmenger syndrome

Pulmonary arterial hypertension (PAH) - a complex and progressive disease that carries significant morbidity and mortality despite optimal medical treatment. Combination therapy for PAH can be more effective than monotherapy. The present randomized trial compared the safety and efficacy of sildenafi...

Full description

Bibliographic Details
Main Authors: Shaadab Mohammed, Rajesh Vijayvergiya, Samir Malhotra, Manoj Kumar Rohit
Format: Article
Language:English
Published: Elsevier 2021-09-01
Series:Indian Heart Journal
Subjects:
Ambrisentan
Combination therapy
Eisenmenger syndrome
Online Access:http://www.sciencedirect.com/science/article/pii/S0019483221001516

Internet

http://www.sciencedirect.com/science/article/pii/S0019483221001516

Similar Items